The FDA's premarket approval (or PMA) process was first established over 30 years ago, but thanks to technology, the development of devices has dramatically changed since then. How should the FDA modernize its premarket approval process to ensure medical device safety? Guests Dr. Rita Redberg, professor of clinical medicine at the University of California, San Francisco, School of Medicine, and director of women's cardiovascular services at the U-C-S-F National Center for Excellence in Women's Health, and Dr. Bram Zuckerman, director of the division of cardiovascular devices at the FDA, discuss current and ongoing research about the quality of the FDA PMA process.
Modernizing the FDA Premarket Approval Process for Medical Devices

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
The FDA's premarket approval (or PMA) process was first established over 30 years ago, but thanks to technology, the development of devices has dramatically changed since then. How should the FDA modernize its premarket approval process to ensure medical device safety? Guests Dr. Rita Redberg, professor of clinical medicine at the University of California, San Francisco, School of Medicine, and director of women's cardiovascular services at the U-C-S-F National Center for Excellence in Women's Health, and Dr. Bram Zuckerman, director of the division of cardiovascular devices at the FDA, discuss current and ongoing research about the quality of the FDA PMA process.
Produced in Cooperation with
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
How COVID-19 Is Affecting Life Outside of the Office: A Dermatologist’s Experience
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Love Story: Lipid Education for Women’s Heart Health
Advancing PBC Care: A Closer Look at Second-Line Therapies
Crossroads in PBC Care: When First-Line Therapy Falls Short
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?